1. Prausnitz MR. Microneedles for transdermal drug delivery. Advanced Drug Delivery Reviews. 2004; 56: 581–7.
2. Ita K. Transdermal Delivery of Drugs with Microneedles-Potential and Challenges. Pharmaceutics. 2015; 7: 90–105.
3. Moreira AF, Rodrigues CF, Jacinto TA, Miguel SP, Costa EC, Correia IJ. Microneedle-based delivery devices for cancer therapy : A review. Pharmacological Research. 2019; 148: 1–11.
4. Singh V, Kesharwani P. Recent advances in microneedles-based drug delivery device in the diagnosis and treatment of cancer. Journal of Controlled Release. 2021; 338: 394–409.
5. Karapetayan L, Luke JJ, Davar D. Toll-Like Receptor 9 Agonists in Cancer. OncoTargets and Therapy. 2020; 13: 10039–60.
6. Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020; 20: 321–34.
7. Milling L, Zhang Y, Irvine DJ. Delivering safer immunotherapies for cancer. Advanced Drug Delivery Reviews. 2017; 114: 79–101.
8. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019; 18: 175–96.
9. Turner JG, White LR, Estrela P, Leese HS. Hydrogel-Forming Microneedles : Current Advancements and Future Trends. Macromolecular Bioscience. 2021; 21: 1–18.
10. Wang PM, Cornwell M, Prausnitz MR. Minimally Invasive Extraction of Dermal Interstitial Fluid for Glucose Monitoring Using Microneedles. Diabetes Technology & Therapeutics. 2005; 7: 131–41.
11. al Sulaiman D, Chang JYH, Bennett NR, et al. Hydrogel-Coated Microneedle Arrays for Minimally Invasive Sampling and Sensing of Specific Circulating Nucleic Acids from Skin Interstitial Fluid. ACS Nano. 2019; 13: 9620.
12. Wiig H, Swartz MA. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev. 2012; 92: 1005–60.
13. Samant PP, Niedzwiecki MM, Raviele N, et al. Sampling interstitial fluid from human skin using a microneedle patch. Science Translational Medicine. 2020; 12: 1–16.
14. Wiig H, Tenstad O, Iversen PO, Kalluri R, Bjerkvig R. Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis & Tissue Repair. 2010; 3.
15. Zhu J, Zhou X, Kim HJ, et al. Gelatin Methacryloyl Microneedle Patches for Minimally Invasive Extraction of Skin Interstitial Fluid. Small. 2020; 16: 1905910.
16. Rudqvist N, Pilones KA, Lhuillier C, Wennerberg E. Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating cells. Cancer Immunology Research. 2019; 6: 139–50.
17. Celis JE, Gromov P, Cabezón T, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment. Molecular and Cellular Proteomics. 2004; 3: 327–44.
18. Espinoza JA, Jabeen S, Batra R, et al. Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. Oncoimmunology [Internet]. 2016; 5: e1248015 (14. Available at: https://doi.org/10.1080/2162402X.2016.1248015
19. Chen L, Zhang C, Xiao J, et al. Local extraction and detection of early stage breast cancers through a microneedle and nano-Ag/MBL film based painless and blood-free strategy. Materials Science and Engineering C. 2020; 109.
20. He R, Niu Y, Li Z, et al. A Hydrogel Microneedle Patch for Point-of-Care Testing Based on Skin Interstitial Fluid. Advanced Healthcare Materials. 2020; 9: 1–11.
21. Zheng M, Wang Z, Chang H, et al. Osmosis-Powered Hydrogel Microneedles for Microliters of Skin Interstitial Fluid Extraction within Minutes. Advanced Healthcare Materials. 2020; 9: 1–11.
22. Mandal A, Boopathy A v., Lam LKW, et al. Cell and fluid sampling microneedle patches for monitoring skin-resident immunity. Science Translational Medicine. 2018; 10.
23. Puigmal N, Dosta P, Solhjou Z, et al. Microneedle-Based Local Delivery of CCL22 and IL-2 Enriches T reg Homing to the Skin Allograft and Enables Temporal Monitoring of Immunotherapy Efficacy. Advanced Functional Materials. 2021; 31: 1–12.
24. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480: 480–9.
25. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. International Immunopharmacology. 2018; 62: 29–39.
26. Hanagata N. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies. Vol. 12, International Journal of Nanomedicine. Dove Medical Press Ltd.; 2017.
27. Dosta P, Ramos V, Borrós S. Stable and efficient generation of poly(β-amino ester)s for RNAi delivery. Molecular Systems Design & Engineering. 2018; 3: 677–89.
28. Dosta P, Segovia N, Cascante A, Ramos V, Borrós S. Surface charge tunability as a powerful strategy to control electrostatic interaction for high efficiency silencing, using tailored oligopeptide-modified poly(beta-amino ester)s (PBAEs). Acta Biomaterialia. 2015; 20: 82–93.
29. Segovia N, Dosta P, Cascante A, Ramos V, Borrós S. Oligopeptide-terminated poly (b-amino ester) s for highly efficient gene delivery and intracellular localization. Acta Biomaterialia. 2014; 10: 2147–58.
30. Dosta P, Tamargo I, Ramos V, et al. Delivery of Anti-microRNA-712 to Inflamed Endothelial Cells Using Poly(β-amino ester) Nanoparticles Conjugated with VCAM-1 Targeting Peptide. Advanced Healthcare Materials. 2021; e2001894.
31. Dosta P, Demos C, Ramos V, et al. Delivery of siRNA to Endothelial Cells In Vivo Using Lysine/Histidine Oligopeptide-Modified Poly(β-amino ester) Nanoparticles. Cardiovascular Engineering and Technology. 2021; 12: 114–25.
32. Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nature Immunology. 2004; 5: 190–8.
33. Buss CG, Bhatia SN. Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics. Proc Natl Acad Sci U S A. 2020; 117: 13428–36.
34. Yuan S, Qiao T, Chen W. CpG Oligodeoxynucleotide 1826 Enhances the Lewis Lung Cancer Response to Radiotherapy in Murine Tumor. Cancer Biotherapy and Radiopharmaceuticals. 2011; 26.
35. Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: Coming of age. Nature Reviews Immunology. 2018; 18: 309–24.
36. Madaan A, Verma R, Singh AT, Jain SK, Jaggi M. A stepwise procedure for isolation of murine bone marrow and generation of dendritic cells. Journal of Biological Methods. 2014; 1: e1.
37. Huang L, Xu H, Peng G. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy. Cellular and Molecular Immunology. 2018; 15: 428–37.
38. Samarasinghe R, Tailor P, Tamura T, Kaisho T, Akira S, Ozato K. Induction of an Anti-Inflammatory Cytokine, IL-10, in Dendritic Cells After Toll-like Receptor Signaling. Vol. 26, Journal of interferon & cytokine research. 2006.
39. Switaj T, Jalili A, Jakubowska AB, et al. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clinical Cancer Research. 2004; 10: 4165–75.
40. Arlauckas SP, Garris CS, Kohler RH, et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Science Translational Medicine. 2017; 9.
41. Lu H. TLR agonists for cancer immunotherapy: Tipping the balance between the immune stimulatory and inhibitory effects. Frontiers in Immunology. 2014; 5: 3–6.
42. Noh JY, Yoon SR, Kim TD, Choi I, Jung H. Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy. Vol. 2020, Journal of Immunology Research. Hindawi Limited; 2020.
43. Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Experimental & Molecular Medicine. 2018; 12: 1–11.
44. Arlauckas SP, Garren SB, Garris CS, et al. Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages. Theranostics. 2018; 8: 5842–54.
45. Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8 + T-CeII recruitment. Cancer Research. 2009; 69: 3077–85.
46. Sideras K, Galjart B, Vasaturo A, et al. Prognostic value of intra-tumoral CD8+/FoxP3+ lymphocyte ratio in patients with resected colorectal cancer liver metastasis. Journal of Surgical Oncology. 2018; 118: 68–76.
47. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene. 2010; 29: 1093–102.
48. Diederichsen ACP, Hjelmborg JVB, Christensen PB, Zeuthen J, Fenge C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunology, Immunotherapy. 2003; 52: 423–8.
49. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology. 2015; 33.
50. Luthria G, Li R, Wang S, et al. In vivo microscopy reveals macrophage polarization locally promotes coherent microtubule dynamics in migrating cancer cells. Nature Communications. 2020; 11.